USAN Council Assigns Pevifoscorvir Sodium As Generic Name For Aligos Therapeutics’ HBV Candidate

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing therapies for liver and viral diseases, announced that the United States Adopted Names (USAN) Council has officially designated “pevifoscorvir sodium” as the nonproprietary (generic) name for ALG-000184, its investigational treatment for chronic hepatitis B virus (HBV) infection.

“The adoption of pevifoscorvir sodium, or pevy, marks the first generic name for a compound at Aligos,” stated Lawrence Blatt, PhD, MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “As we continue to progress our Phase 2 B-Supreme study, we look forward to adopting this new name. This milestone showcases our continued innovation in the liver and viral disease space and reinforces our commitment to improving patient outcomes.”

The USAN Council, which includes representatives from the U.S. Food and Drug Administration (FDA), American Medical Association (AMA), United States Pharmacopeia (USP), and the American Pharmacists Association (APhA), is responsible for assigning clear and distinctive nonproprietary names to drug substances. These names are essential for ensuring consistency and clarity across healthcare systems.

By receiving its official USAN designation, pevifoscorvir sodium achieves a standardized identity that facilitates global recognition and regulatory transparency. The move marks a significant step forward in the drug’s development, reflecting Aligos Therapeutics’ commitment to advancing innovative treatments that improve outcomes for patients living with chronic HBV.